NCT04604704 - Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

January 23, 2023

Study Completion Date

January 23, 2023

Conditions

Covid19Long COVID-19Post-COVID-19 Syndrome

Interventions

DRUG

Naltrexone

Naltrexone at 4.5 mg/day

DIETARY_SUPPLEMENT

NAD+

NAD+ will be applied using iontophoresis patches. The patches will be provided by ready-made NAD+ solutions (400 mg) to be applied to the positive electrode of the patch and saline to the negative electrode. The patch is powered by a self-contained battery, producing an electric current to facilitate NAD+ absorption through the skin into the blood. Patches are worn for 4-6 hours once a week.

Trial Locations (1)

48104

AgelessRx, Ann Arbor